Effect of bucladesine, pentoxifylline, and H‐89 as cyclic adenosine monophosphate analog, phosphodiesterase, and protein kinase A inhibitor on acute pain

The aim of this study was to determine the effects of cyclic adenosine monophosphate (cAMP) and its dependent pathway on thermal nociception in a mouse model of acute pain. Here, we studied the effect of H‐89 (protein kinase A inhibitor), bucladesine (Db‐cAMP) (membrane‐permeable analog of cAMP), an...

Full description

Saved in:
Bibliographic Details
Published in:Fundamental & clinical pharmacology 2017-08, Vol.31 (4), p.411-419
Main Authors: Salehi, Forouz, Hosseini‐Zare, Mahshid S., Aghajani, Haleh, Seyedi, Seyedeh Yalda, Hosseini‐Zare, Maryam S., Sharifzadeh, Mohammad
Format: Article
Language:English
Subjects:
Acute Pain - drug therapy
Acute Pain - enzymology
Adenosine monophosphate
Animals
Bucladesine - pharmacology
Bucladesine - therapeutic use
cGMP
cyclic adenosine monophosphate
Cyclic AMP
Cyclic AMP - analogs & derivatives
Cyclic GMP
Dose-Response Relationship, Drug
Enzyme inhibitors
Inhibitors
Intracellular signalling
Isoquinolines - pharmacology
Isoquinolines - therapeutic use
Kinases
Male
Mice
Pain
Pain Measurement - drug effects
Pain Measurement - methods
Pain perception
Pentoxifylline - pharmacology
Pentoxifylline - therapeutic use
Pharmacology
Phosphodiesterase
phosphodiesterase inhibitor
Phosphodiesterase Inhibitors - pharmacology
Phosphodiesterase Inhibitors - therapeutic use
Protein kinase A
Proteins
Sulfonamides - pharmacology
Sulfonamides - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to determine the effects of cyclic adenosine monophosphate (cAMP) and its dependent pathway on thermal nociception in a mouse model of acute pain. Here, we studied the effect of H‐89 (protein kinase A inhibitor), bucladesine (Db‐cAMP) (membrane‐permeable analog of cAMP), and pentoxifylline (PTX; nonspecific phosphodiesterase (PDE) inhibitor) on pain sensation. Different doses of H‐89 (0.05, 0.1, and 0.5 mg/100 g), PTX (5, 10, and 20 mg/100 g), and Db‐cAMP (50, 100, and 300 nm/mouse) were administered intraperitoneally (I.p.) 15 min before a tail‐flick test. In combination groups, we injected the first and the second compounds 30 and 15 min before the tail‐flick test, respectively. I.p. administration of H‐89 and PTX significantly decreased the thermal‐induced pain sensation in their low applied doses. Db‐cAMP, however, decreased the pain sensation in a dose‐dependent manner. The highest applied dose of H‐89 (0.5 mg/100 g) attenuated the antinociceptive effect of Db‐cAMP in doses of 50 and 100 nm/mouse. Surprisingly, Db‐cAMP decreased the antinociceptive effect of the lowest dose of H‐89 (0.05 mg/100 g). All applied doses of PTX reduced the effect of 0.05 mg/100 g H‐89 on pain sensation; however, the highest dose of H‐89 compromised the antinociceptive effect of 20 mg/100 g dose of PTX. Co‐administration of Db‐cAMP and PTX increased the antinociceptive effect of each compound on thermal‐induced pain. In conclusion, PTX, H‐89, and Db‐cAMP affect the thermal‐induced pain by probably interacting with intracellular cAMP and cGMP signaling pathways and cyclic nucleotide‐dependent protein kinases.
ISSN:0767-3981
1472-8206
DOI:10.1111/fcp.12282